Nørgaard et al. (2022) compared cardiovascular outcomes between GLP-1 RAs and SGLT-2 inhibitors, another class of diabetes medications with established cardiovascular benefits [25]. The gene discussed is SLC5A2; the disease is diabetes mellitus.